Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5428818 | 0.93 | DRD2 (0.43) | DRD2DRD3 | |
| Formic Acid SCHEMBL5421453 | 0.85 | DRD2 (0.41) | DRD2DRD3 | |
| SCHEMBL4072791 | 0.84 | DRD2 (0.49) | DRD2DRD3 | |
| Formic Acid SCHEMBL4063515 | 0.81 | DRD2 (0.42) | DRD2DRD3 | |
| SCHEMBL5421460 | 0.79 | DRD2 (0.40) | DRD2DRD3 | |
| SCHEMBL4063518 | 0.79 | DRD2 (0.46) | DRD2DRD3 | |
| SCHEMBL4072788 | 0.79 | DRD2 (0.44) | DRD2DRD3 | |
| SCHEMBL4065332 | 0.77 | DRD2 (0.52) | DRD2DRD3 | |
| SCHEMBL4065338 | 0.77 | DRD2 (0.52) | DRD2DRD3 | |
| SCHEMBL4063600 | 0.76 | DRD2 (0.50) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | CHRM3, CHRNG, CHRM2 | DRD2 969/4885DRD3 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.